ArticleRSC advances2023
Unsupported nanoporous gold catalyst for highly selective hydroamination of alkynes.
Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An efficient and highly selective heterogeneous catalyst system for hydroamination of alkynes was developed using unsupported gold nanopores (AuNPore) for the first time. The AuNPore-catalyzed highly regioselective hydroamination of alkynes proceeded smoothly without any additive and solvent under mild conditions (rt-50 °C) to yield Markovnikov imines in satisfactory to excellent yields. No gold leached from AuNPore during the hydroamination of alkynes. Moreover, the catalyst was easily recovered and reused without any loss of catalytic activity. A one-pot, two-step procedure using a single AuNPore catalyst has been devised to produce secondary amines derived from readily available alkynes and anilines with high atom efficiency.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.